Laekna published an annual results announcement for FY 2025, reporting revenue of RMB106.72 million and gross profit of RMB86.42 million. FY 2025 loss for the year narrowed 9.82% to RMB229.32 million, while total comprehensive loss widened 5.51% to RMB253.71 million. R&D expenses rose 16.2% to RMB249.9 million, which Laekna attributed mainly to higher spending on its ActRII portfolio (LAE102, LAE103 and LAE123) and increased equity-settled share-based payment expenses. Cash and bank balances increased 95.3% to RMB1.24 billion, and bank loans rose 18.58% to RMB117.41 million. On the pipeline, Laekna said Phase III recruitment for LAE002 plus fulvestrant (AFFIRM-205) in China was completed, with topline data targeted for the first half of 2026, and it also reported Phase I updates for LAE102 and the start of Phase I dosing for LAE103 in Australia.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260318-12057738), on March 18, 2026, and is solely responsible for the information contained therein.
Comments